Zempic, Wegovy, and Mounjaro, a new class of anti-obesity medications, are heralded as paradigm-shifting, unprecedented, and revolutionary. They represent a significant change in the treatment of obesity.
In order to effectively suppress appetite and promote weight reduction, these prescription drugs mimic gut hormones by slowing stomach emptying and releasing insulin. Because they work so well, the demand for these medications is soaring.
These drugs cause people to reevaluate lifestyle issues even though they help with weight loss. Scientists at the University of Kansas Medical Centre, such as Renee Rogers, Ph.D., and John Jakicic, Ph.D., investigate the benefits of exercise when taken in addition to anti-obesity drugs.
According to their research, exercise has more health benefits than just helping people lose weight. These benefits include improved muscle and cardiovascular strength.
The Obesity Society’s publication, Obesity, published a paper by Jakicic and Rogers suggesting a change in the recommended amount of exercise for people taking anti-obesity medications. You may no longer need to exercise for the traditional 200–300 minutes a week to lose weight.
Reducing sedentary behaviour should be the main goal instead, and two days a week of resistance training and 150 minutes of moderate-intensity exercise should be allocated to this.
Regarding the loss of lean mass that comes with weight loss caused by medicine, the researchers emphasize the need of giving muscle quality a higher priority than muscle number. Beyond simply increasing muscle mass, resistance exercise improves insulin and glucose regulation in the muscles as well as their functionality.
A study to investigate the relationship between these drugs, weight loss, and exercise is being started by researchers at the University of Kansas. Providing evidence for better future therapies is their way of improving care for people who depend on these ground-breaking medications.
